Low Stromal Area and High Stromal Microvessel Density Predict Poor Prognosis in Pancreatic Cancer
Authors:
- Hideyuki YoshitomiHYHideyuki Yoshitomi
- Shigetsugu TakanoSTShigetsugu Takano
- Shingo KagawaSKShingo Kagawa
- Hiroaki ShimizuHSHiroaki Shimizu
- Masayuki OhtsukaMOMasayuki Ohtsuka
- Atsushi KatoAKAtsushi Kato
- Katsunori FurukawaKFKatsunori Furukawa
- Masaru MiyazakiMasaru Miyazaki
- 1 April 2016
- journal article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 45 (4) , 593-600
Abstract
Excessive stroma is a unique property of cancer tissue of the pancreas. The aim of this study was to analyze the relationship of cancer stromal area (SA) and tumor microvessel density (MVD) with prognostic and clinicopathological findings. Pancreatic adenocarcinoma tissues obtained from 104 patients were subjected to cytokeratin 19 and CD31 double immunostaining to identify cancer cells and endothelial cells simultaneously. Stromal area and MVD were assessed in the same sections. Patients were divided into 2 groups for each analysis by the median value of the respective measure. Stromal area negatively correlated with MVD. The low SA group harbored more poorly differentiated carcinoma than the high SA group. Patients of the low SA group showed a higher incidence of hematogenous recurrence. As a consequence, patients in the low SA and the high MVD groups had poorer prognosis in terms of both disease-free survival and overall survival than their respective groups. Multivariate analysis showed that a low SA was an independent prognostic factor for disease-free and overall survival. Our data indicate that the stroma of pancreatic cancer may play an auxiliary role as a barrier to cancer cell invasion. The depletion of tumor stroma alone does not suppress pancreatic cancer progression.Keywords
This publication has 24 references indexed in Scilit:
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Recent progress in pancreatic cancerCA: A Cancer Journal for Clinicians, 2013
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- The role of stroma in pancreatic cancer: diagnostic and therapeutic implicationsNature Reviews Gastroenterology & Hepatology, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–αScience, 2010
- Specific Expression of Endoglin (CD105) in Endothelial Cells of Intratumoral Blood and Lymphatic Vessels in Pancreatic CancerPancreas, 2008
- The Activated Stroma Index Is a Novel and Independent Prognostic Marker in Pancreatic Ductal AdenocarcinomaClinical Gastroenterology and Hepatology, 2008
- Tumor-stroma interactions in pancreatic ductal adenocarcinomaMolecular Cancer Therapeutics, 2007
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997